These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37775361)

  • 1. Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Feng M; Matoso A; Epstein G; Fong M; Park YH; Gabrielson A; Patel S; Czerniak B; Compérat E; Hoffman-Censits J; Kates M; Kim S; McConkey D; Choi W
    Eur Urol; 2024 Apr; 85(4):e122-e123. PubMed ID: 37775361
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Wang Z; Zeng S; Xu C
    Eur Urol; 2024 Apr; 85(4):e113-e114. PubMed ID: 37919193
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Inamura K
    Eur Urol; 2024 Apr; 85(4):e120-e121. PubMed ID: 37696739
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Mattias Höglund's Letter to the Editor re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020.
    Klümper N; Cox A; Eckstein M
    Eur Urol; 2023 Aug; 84(2):e51-e52. PubMed ID: 37244816
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    Loehr A; Chowdhury S; Abida W
    Eur Urol; 2023 Mar; 83(3):e78. PubMed ID: 36623951
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
    Uleri A; Baboudjian M; Diamand R; Ploussard G
    Eur Urol; 2024 Sep; 86(3):e72. PubMed ID: 38796380
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Shun-Fa Hung, Shyi-Chun Yii, and Shiu-Dong Chung's Letter to the Editor re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.012.
    He P; Zhou X; Chen Z
    Eur Urol; 2022 May; 81(5):e119. PubMed ID: 35125227
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Kuo-Chin Hung and Chia-Ter Chao's Letter to the Editor re: Jennifer Kranz, Riccardo Bartoletti, Franck Bruyère, et al. European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.03.035.
    Kranz J; Bonkat G
    Eur Urol; 2024 Jul; ():. PubMed ID: 38987084
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Behnam Shakiba's Letter to the Editor re: Emilien Seizilles de Mazancourt, Juliette Cotte, Caroline Plassais, et al. Sexual and Moral Harassment of French Urologists in Training and Barriers to Reporting: Results from a National Survey. Eur Urol. 2024;85:e162-e163.
    Seizilles de Mazancourt E; Kaulanjan K
    Eur Urol; 2024 Aug; 86(2):e41. PubMed ID: 38388257
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Røder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
    Uleri A; Baboudjian M; Diamand R; Ploussard G
    Eur Urol; 2024 Sep; 86(3):e66. PubMed ID: 38796382
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Yudai Ishiyama and Fumihiko Urabe's Letter to the Editor re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006.
    Takemura K; Yuasa T; Choueiri TK; Heng DYC
    Eur Urol; 2024 Mar; ():. PubMed ID: 38531704
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Meny Lv, Xufei Luo, and Yaolong Chen's Letter to the Editor re: Mauro Gacci, Vasileios I. Sakalis, Markos Karavitakis, et al. European Association of Urology Guidelines on Male Urinary Incontinence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.05.012.
    Gacci M; Sakalis VI; Karavitakis M; Gravas S
    Eur Urol; 2022 Oct; 82(4):e119-e120. PubMed ID: 35945088
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012.
    Kerkmeijer LGW; Pos FJ; van der Heide UA; Israël B; Draulans C; Haustermans K
    Eur Urol; 2022 Jun; 81(6):e147-e148. PubMed ID: 35339319
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Ping Zhong, Xin Liu, and Limin Liao's Letter to the Editor re: Michele Gnech, Lisette 't Hoen, Alexandra Zachou, et al. Update and Summary of the European Association of Urology/European Society of Paediatric Urology Paediatric Guidelines on Vesicoureteral Reflux in Children. Eur Urol. 2024;85:433-42.
    Gnech M; 't Hoen L; Burgu B; Radmayr C
    Eur Urol; 2024 Oct; 86(4):e95. PubMed ID: 38735821
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Tan WS; Kelly JD;
    Eur Urol; 2023 Jan; 83(1):e29-e30. PubMed ID: 36272948
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
    Valle LF; Kishan AU
    Eur Urol; 2021 Jul; 80(1):e15-e16. PubMed ID: 33934928
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
    Trock BJ; Karnes RJ
    Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Giancarlo Marra, Marco Oderda, Paolo Gontero, and Lorenzo Richiardi's Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
    Hu JC; Allaf ME; Vickers AJ; Schaeffer EM
    Eur Urol; 2024 Aug; 86(2):e38-e39. PubMed ID: 38599991
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016.
    Garcia-Ruiz A; Macarro C; Mateo J; Perez-Lopez R
    Eur Urol; 2024 Sep; 86(3):e69-e70. PubMed ID: 38760292
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033.
    Liedberg F; Kollberg P; Allerbo M; Baseckas G; Brändstedt J; Gudjonsson S; Hagberg O; Håkansson U; Jerlström T; Löfgren A; Patschan O; Sörenby A; Bläckberg M
    Eur Urol; 2020 Nov; 78(5):e186-e187. PubMed ID: 32950295
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.